NCT00512291View on ClinicalTrials.gov

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2009

Conditions
Advanced Cancer
Interventions
DRUG

Olanzapine

5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00512291 - Subcutaneous Olanzapine for Hyperactive or Mixed Delirium | Biotech Hunter | Biotech Hunter